20 December 2018 - - US-based biotechnology company Carmot Therapeutics has initiated a clinical trial for the treatment of type 2 diabetes with CT-868, a dual modulator of the GLP-1 and GIP incretin receptors, the company said.

The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of CT-868 in overweight or obese but otherwise healthy volunteers and patients with type 2 diabetes.

This Phase 1 study is a randomised, double-blind, placebo-controlled, dose escalation trial in overweight or obese healthy volunteers and patients with type 2 diabetes.

The first phase of the study will evaluate CT-868 in single ascending doses. The second phase of the study will consist of multiple ascending doses over 14 days.

The third phase will evaluate repeat dosing of CT-868 in patients with type 2 diabetes over a 28-day period and will include additional assessments of body weight and body fat composition.

Carmot Therapeutics is a biotechnology company dedicated to the discovery and development of innovative medicines.

Carmot applies a transformative and patented drug discovery approach, Chemotype Evolution, to overcome major limitations in existing discovery methods, providing Carmot a unique opportunity to tackle challenging disease targets and identify superior therapeutics.

The company is applying Chemotype Evolution internally and in collaboration with industry partners such as Amgen and Genentech.

Carmot has identified drug leads targeting class-B GPCRs, protein-protein interactions, and deubiquitinating enzymes and is advancing a portfolio of wholly-owned programmes in metabolic disease and oncology.